BrainStorm Cell Therapeutics announced a net loss of $2.1 million for Q1 2026 while progressing with preparations for its Phase 3b ENDURANCE trial of NurOwn, a stem cell therapy for ALS. The trial aims to enroll about 200 patients to test NurOwn's effectiveness in early-stage ALS. The company secured $2.2 million in recent private placements to support operations and trial readiness. Successful trial completion could lead to a new Biologics License Application for NurOwn, addressing a critical need for ALS treatments.
On Holding, a Swiss athletic shoe company, is expanding into the global football market by partnering with soccer star Kylian Mbappé, who leaves Nike after nearly 20 years. This marks On Holding's first venture into football cleats and apparel, lever...
Peter Thiel's investment fund, which held no stocks for two consecutive quarters, has made a significant comeback with $419 million in new investments. Notably, 72% of this capital has been allocated to the energy and power sectors, signaling a strat...
Ennis, Inc. has been downgraded from Buy to Hold due to challenging industry conditions, even though its profitability remains stable. Recent acquisitions have helped offset declines in organic revenue, but demand in the US printing market continues ...
Solana's price surged to $112.41, its highest in seven months, rising 11.5% in one day due to a combination of market recovery, forced short position liquidations, and a network upgrade that shortened block times. The upgrade reduces the epoch length...
GreenPower Motor Company announced that its CEO, Fraser Atkinson, converted Series B convertible preferred shares held by companies he controls into common shares, increasing his ownership stake from 17.5% to 28.6%. This transaction, exempt from mino...
